Safety and tolerability in patients with hepatic impairment will be assessed by adverse events (AEs), serious adverse events (SAEs) and out of range lab values [ Time Frame: at completion of the study ] [ Designated as safety issue: Yes ]

To evaluate the preliminary anti-tumor activity which will be assessed by radiological scans every 6 weeks [ Time Frame: at completion of the study ] [ Designated as safety issue: Yes ]

Original Primary Outcome Measures ICMJE (submitted: January 10, 2007)

Safety and tolerability in patients with hepatic impairment will be assessed by AEs, SAEs and out of range lab values.

Radiological scans will also be completed approximately every 6 weeks to asses anti-tumor activity.

Completion of the core study is required for participation in the extension.

18 years of age or older

World Health Organization (WHO) Performance Status score of: 0 - you are fully active and more or less as you were before your illness; 1 - you cannot carry out heavy physical work, but can do anything else; or 2 - you are up and about more than half the day, you can look after yourself, but are not well enough to work.

Life expectancy of 3 months or more

Patients with measurable or evaluable disease who have histologically documented advanced solid tumor and who have progressed after systemic therapy or for whom standard systemic therapy does not exist

Exclusion Criteria:

Severe and/or uncontrolled medical disease

Known diagnosis of human immunodeficiency virus (HIV) infection

Presence of any other active or suspected acute or chronic uncontrolled infection